EPIX: Clinical Update on Phase 1 Monotherapy Trial of EPI-7386 Expected in 2Q22…
By David Bautz, PhD
NASDAQ:EPIX
READ THE FULL EPIX RESEARCH REPORT
CFRX: Results from Interim Futility Analysis in July 2022…
By David Bautz, PhD
NASDAQ:CFRX
READ THE FULL CFRX RESEARCH REPORT
SYTA: Siyata Mobile Reports 1st Quarter 2022 Results and Updates the Investor Community on Key Product Categories.
By Thomas Kerr, CFA
NASDAQ:SYTA
READ THE FULL SYTA RESEARCH REPORT
RVPH: First Quarter Results
By John Vandermosten, CFA
NASDAQ:RVPH
READ THE FULL RVPH RESEARCH REPORT
VIRI: Enrollment Complete in FORTRESS Trial; Results Expected in September 2022…
By David Bautz, PhD
NASDAQ:VIRI
READ THE FULL VIRI RESEARCH REPORT
RCRT: Q1 2022 Starts the Year With 117% Revenues Growth and Declining Losses
By Lisa Thompson
NASDAQ:RCRT
READ THE FULL RCRT RESEARCH REPORT
ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway…
By David Bautz, PhD
NASDAQ:ARWR
READ THE FULL ARWR RESEARCH REPORT
POET: Could POET’s Biggest Market Be AI Accelerators?
By Lisa Thompson
NASDAQ:POET
READ THE FULL POET RESEARCH REPORT
LGVN: CEO Leaving but Progress Continues
By Brad Sorensen, CFA
NASDAQ:LGVN
READ THE FULL LGVN RESEARCH REPORT
ACHV: First Quarter 2022 Results
By John Vandermosten, CFA
NASDAQ:ACHV
READ THE FULL ACHV RESEARCH REPORT